| Carcinogenesis 1: Hormonal Carcinogenesis |
| Carcinogenesis 2: Molecular Carcinogenesis |
| Cellular, Molecular, and Tumor Biology 1: Angiogenesis Inhibitors I |
| Cellular, Molecular, and Tumor Biology 2: Angiogenesis Inhibitors II |
| Cellular, Molecular, and Tumor Biology 3: Cell Membrane and Cytoplasmic Signaling Pathways |
| Clinical Research 1: Drug Resistance, Pharmacogenomics, and Pharmacokinetics |
| Clinical Research 2: Molecular Diagnosis and Prognosis I |
| Endocrinology 1: Endocrinology I |
| Epidemiology 1: Viral, Bacterial, and Dietary Exposures |
| Experimental and Molecular Therapeutics 1: ABC Transporters in Drug Resistance |
| Experimental and Molecular Therapeutics 2: Drug Accumulation and Metabolism as Mechanisms of Drug Resistance |
| Experimental and Molecular Therapeutics 3: Investigational Combinations/Modulators I |
| Experimental and Molecular Therapeutics 4: Mechanisms of Action |
| Experimental and Molecular Therapeutics 5: Molecular Profiling of Drug Resistance |
| Experimental and Molecular Therapeutics 6: Novel Delivery Strategies |
| Immunology/Tumor Immunobiology 1: Lymphokines, Cytokines, and Growth Factors in Tumor Immunity I |
| Immunology/Tumor Immunobiology 2: Tumors and the Immune System: Immunotherapy and Immunomodulation I |
| Integrated Session 1: Growth Factors and Antibodies in Tumor Immunotherapy |
| Prevention Research 1: Chemoprevention Studies I |
| Carcinogenesis 3: Premalignant Lesions/Oxidative Stress |
| Cellular, Molecular, and Tumor Biology 15: Cell and Animal Cancer Models |
| Cellular, Molecular, and Tumor Biology 16: Cell Cycle Control and Checkpoints |
| Cellular, Molecular, and Tumor Biology 17: Cell Cycle Targeted Therapeutic Agents |
| Cellular, Molecular, and Tumor Biology 18: Cytoplasmic Signaling |
| Cellular, Molecular, and Tumor Biology 19: DNA Methylation: Markers |
| Cellular, Molecular, and Tumor Biology 20: Genomic Instability |
| Cellular, Molecular, and Tumor Biology 21: Imaging/Tumor Markers |
| Cellular, Molecular, and Tumor Biology 22: Mechanisms of Transcriptional Regulation II |
| Cellular, Molecular, and Tumor Biology 23: Senescence, Telomeres, and Telomerase |
| Chemistry 1: Chemical Topics in Drug Therapy, Radiation Therapy, Imaging, and Structure Biology |
| Clinical Research 3: Molecular Classification of Tumors |
| Clinical Research 4: Molecular Diagnosis and Prognosis II |
| Epidemiology 2: Epidemiology of Breast and Prostate Cancer |
| Epidemiology 3: Immune Response and Exposure Modifying Genes in Diverse Neoplasms |
| Experimental and Molecular Therapeutics 7: Cellular Responses to Alkylating Agents |
| Experimental and Molecular Therapeutics 8: Diagnostic Markers, Imaging, and Microarrays |
| Experimental and Molecular Therapeutics 9: Gene Therapy I |
| Experimental and Molecular Therapeutics 10: Novel Mechanisms of Drug Resistance |
| Experimental and Molecular Therapeutics 11: Specific Immune Mechanisms and Cancer Vaccines: Clinical Studies |
| Immunology/Tumor Immunobiology 3: Specific Immunomechanisms and Cancer Vaccines: Basic Studies I |
| Integrated Session 2: Cell Signaling and Apoptosis after Radiation |
| Integrated Session 3: Clinical Cancer Genetics |
| Integrated Session 4: Clinical Prevention Studies |
| Integrated Session 5: Modification of Radiation Sensitivity |
| Prevention Research 2: Biological and Biochemical Mechanisms in Prevention |
| Supportive Care and Survivorship Research 1: Psychosocial Research in Cancer |
| Clinical Research 5: Emerging Concepts and Targets in Immunotherapy |
| Carcinogenesis 4: DNA Damage and Repair |
| Cellular, Molecular, and Tumor Biology 24: Transcriptional Control of Cell Survival |
| Cellular, Molecular, and Tumor Biology 25: Tumor Microenvironment |
| Clinical Research 6: Novel Prognostic and Predictive Factors |
| Endocrinology 2: Endocrinology II |
| Epidemiology 4: DNA Repair Genotype/Phenotype II |
| Experimental and Molecular Therapeutics 12: New Targets, Agents, and Delivery Strategies |
| Experimental and Molecular Therapeutics 13: Novel Therapeutic Agents I |
| Carcinogenesis 5: Animal and In Vitro Models for Carcinogenesis I |
| Carcinogenesis 6: DNA Damage and Repair I |
| Cellular, Molecular, and Tumor Biology 26: Chromatin Structure and Transcriptional Regulation |
| Cellular, Molecular, and Tumor Biology 27: DNA Methylation Inhibition |
| Cellular, Molecular, and Tumor Biology 28: Functional Genomics |
| Cellular, Molecular, and Tumor Biology 29: Gene Expression Studies: Technology, Informatics, and Cancer Biology |
| Cellular, Molecular, and Tumor Biology 30: Genome-wide Analysis in Brain Tumors and Animal Models |
| Cellular, Molecular, and Tumor Biology 31: Genome-wide Screening for Cancer-related Genes I |
| Cellular, Molecular, and Tumor Biology 32: Genomics/Proteomics to Study Tumor Progression |
| Cellular, Molecular, and Tumor Biology 33: Inflammation and Metastasis |
| Cellular, Molecular, and Tumor Biology 34: Molecular Alterations in Genitourinary Tumors |
| Cellular, Molecular, and Tumor Biology 35: Proteases and Protease Inhibitors |
| Cellular, Molecular, and Tumor Biology 36: Therapies against Tumor Invasion and Metastasis |
| Cellular, Molecular, and Tumor Biology 37: Tobacco-related Malignancies: Tumors of the Head and Neck and Lung |
| Chemistry 2: Chemical Aspects of Carcinogenesis |
| Clinical Research 7: Molecular Markers of Metastasis and Progression |
| Endocrinology 3: Endocrinology III |
| Epidemiology 5: Biomarkers of Human Exposure to Carcinogens |
| Experimental and Molecular Therapeutics 14: Investigational Combinations/Modulators II |
| Experimental And Molecular Therapeutics 14: Investigational Combinations/Modulators II |
| Experimental and Molecular Therapeutics 15: Molecular Pharmacology, Pharmacokinetics and Pharmacogenomics |
| Experimental and Molecular Therapeutics 16: Novel Agents: Targets and Mechanisms |
| Experimental and Molecular Therapeutics 17: Novel Screens/Targets and Dosing Approaches |
| Experimental and Molecular Therapeutics 18: Pharmacogenomics, Preclinical Toxicology, Pharmacokinetics |
| Experimental and Molecular Therapeutics 19: Reversing or Overcoming Drug Resistance |
| Immunology/Tumor Immunobiology 4: Specific Immunomechanisms and Cancer Vaccines: Basic Studies II |
| Immunology/Tumor Immunobiology 5: Tumors and the Immune System: Immunotherapy and Immunomodulation II |
| Integrated Session 6: Immunotherapy and Combined Modality Approaches |
| Prevention Research 3: Molecular Targets for Cancer Prevention: Development of New Agents |
| Experimental and Molecular Therapeutics 20: Gene Expression Profiling of Drug Action |
| Cellular, Molecular, and Tumor Biology 38: Cancer Genetics: Searching for New Genes and Molecular Markers |
| Cellular, Molecular, and Tumor Biology 39: DNA Repair and Genomic Instability |
| Cellular, Molecular, and Tumor Biology 40: Proteases and Tumor Invasion |
| Chemistry 3: DNA as a Target for Drugs and Carcinogens |
| Epidemiology 6: Endogenous and Exogenous Factors in Breast and Prostate Cancer |
| Experimental and Molecular Therapeutics 21: Cell Cycle Checkpoint and Kinase Inhibition |
| Experimental and Molecular Therapeutics 22: Novel Strategies for Gene Delivery |
| Immunology/Tumor Immunobiology 6: Molecular and Cellular Mechanisms of Antitumor Immunity |
| Cellular, Molecular, and Tumor Biology 41: Angiogenesis II: Novel Agents, Mechanisms, and Targets |
| Cellular, Molecular, and Tumor Biology 42: Genetic Regulation of Metastasis |
| Cellular, Molecular, and Tumor Biology 43: Oncogenic Transcription Factors |
| Cellular, Molecular, and Tumor Biology 44: Senescence and Immortalization |
| Cellular, Molecular, and Tumor Biology 45: Signaling and Therapeutics |
| Cellular, Molecular, and Tumor Biology 46: Signaling and Tumor Invasion |
| Experimental and Molecular Therapeutics 23: Histone Deacetylase Inhibitors |
| Experimental and Molecular Therapeutics 24: Novel Mechanisms of Drug Resistance and Functional Characterization |
| Immunology/Tumor Immunobiology 7: Innovative Approaches to Immunotherapy of Tumors |
| Chemistry 4: SAR and Structural Biology Studies of Drug Candidates |
| Carcinogenesis 7: Environmental Carcinogenesis and Tumor Progression |
| Cellular, Molecular, and Tumor Biology 47: Analysis of p53-MDM2-ARF Pathways |
| Cellular, Molecular, and Tumor Biology 48: Angiogenesis I: Inhibitors of VEGF and VEGF-Receptors |
| Cellular, Molecular, and Tumor Biology 49: Cyclins and Cyclin-dependent Kinases |
| Cellular, Molecular, and Tumor Biology 50: DNA Damage and Repair II |
| Cellular, Molecular, and Tumor Biology 51: DNA Damage and Repair III |
| Cellular, Molecular, and Tumor Biology 52: Molecular Alterations in Prostate Cancer |
| Cellular, Molecular, and Tumor Biology 53: Molecular Markers I |
| Cellular, Molecular, and Tumor Biology 54: Pediatric Oncology |
| Cellular, Molecular, and Tumor Biology 55: Receptor Signaling |
| Cellular, Molecular, and Tumor Biology 56: Regulatory Mechanisms in Skin Tumorigenesis |
| Cellular, Molecular, and Tumor Biology 57: Stem Cell Biology |
| Cellular, Molecular, and Tumor Biology 58: Transcriptional Control of Cellular Activities |
| to come |
| Cellular, Molecular, and Tumor Biology 59: Tumor Classification and Genome and Transcriptome Scanning |
| Endocrinology 4: Endocrinology IV |
| Epidemiology 7: DNA Repair Genotype/Phenotype I |
| Epidemiology 8: Methods, Genotype/Phenotype and Carcinogen Metabolism Genes |
| Experimental and Molecular Therapeutics 25: Apoptotic Pathways and the Immune System |
| Experimental and Molecular Therapeutics 26: Molecular Targets of Antimetabolites |
| Experimental and Molecular Therapeutics 27: Natural Products |
| Experimental and Molecular Therapeutics 28: Novel Targets and Approaches for Angiogenesis and Signaling Pathways |
| Experimental and Molecular Therapeutics 29: Novel Therapeutic Agents II |
| Experimental and Molecular Therapeutics 30: Target Identification |
| Experimental and Molecular Therapeutics 31: Topoisomerase, Telomerase, and Nucleosides/Nucleotides |
| Integrated Session 7: Pediatric Oncology |
| Integrated Session 8: Radiation: Normal Tissue Damage, Protectors, and Predictive Assays |
| Prevention Research 5: Chemoprevention Studies II |
| Prevention Research 6: Molecular Markers in Prevention Research |
| Carcinogenesis 8: Chemical Carcinogenesis |
| Carcinogenesis 9: Molecular and Viral Carcinogenesis |
| Cellular, Molecular, and Tumor Biology 60: Angiogenic Gene Expression in Malignancy |
| Cellular, Molecular, and Tumor Biology 61: Bioinformatics: Genomics, Transcriptomics, and Systems Biology of Cancer |
| Cellular, Molecular, and Tumor Biology 62: Biomarkers for Metastasis |
| Cellular, Molecular, and Tumor Biology 63: Biomarkers for Tumor Progression |
| Cellular, Molecular, and Tumor Biology 64: Bone Metastasis |
| Cellular, Molecular, and Tumor Biology 65: Cell Surface Death Pathways I |
| Cellular, Molecular, and Tumor Biology 66: Cell Surface Death Pathways II |
| Cellular, Molecular, and Tumor Biology 67: Gene Regulation and Tumor Invasion |
| Cellular, Molecular, and Tumor Biology 68: Genome-wide Screening for Cancer-related Genes II |
| Cellular, Molecular, and Tumor Biology 69: MAP Kinase Cascade Signaling |
| Cellular, Molecular, and Tumor Biology 70: Molecular Alterations in Mammary Tumorigenesis |
| Cellular, Molecular, and Tumor Biology 71: PI3K/ AKT Signaling |
| Cellular, Molecular, and Tumor Biology 72: Proteomic Pattern Analysis for Cancer Diagnosis and Treatment |
| Cellular, Molecular, and Tumor Biology 73: Regulation of TRAIL-induced Apoptosis |
| Cellular, Molecular, and Tumor Biology 74: Regulators of Increased Angiogenesis |
| Cellular, Molecular, and Tumor Biology 75: siRNA and Gene Silencing |
| Cellular, Molecular, and Tumor Biology 76: Therapeutic and Diagnostic Marker Discovery Using Proteomics |
| Clinical Research 8: Laboratory Correlates/New Targeted Agents/Methodology for New Study Design |
| Clinical Research 9: Molecular Detection of Metastasis and Genetic Alteration in Cancer |
| Epidemiology 9: Risk Factors and Modeling |
| Experimental and Molecular Therapeutics 32: Cellular Pharmacology and Pharmacogenomics |
| Experimental and Molecular Therapeutics 33: Gene Therapy II |
| Experimental and Molecular Therapeutics 34: Genes, Drugs, and Novel Agents |
| Experimental and Molecular Therapeutics 35: Preclinical Models/Pharmacology/Mechanisms |
| Experimental and Molecular Therapeutics 36: Signal Transduction Inhibitors |
| Experimental and Molecular Therapeutics 37: Signaling Targets |
| Prevention Research 7: Diet and Cancer |
| Cellular, Molecular, and Tumor Biology 77: Cytoplasmic and Nuclear Signaling |
| Cellular, Molecular, and Tumor Biology 78: Host and Tumor Genomic Instability |
| Cellular, Molecular, and Tumor Biology 79: Ubiquitin Ligases and Associated Kinases at Key Cell Cycle Checkpoints |
| Clinical Research 10:: Early Detection: Strategies and Technologies |
| Clinical Research 10: Early Detection: Strategies and Technologies |
| Epidemiology 10: Smoking and Cancer: Lung, Head and Neck, and Bladder Cancer |
| Experimental and Molecular Therapeutics 38: Novel Therapeutic Agents III: Signaling Inhibitors |
| Experimental and Molecular Therapeutics 39: Novel Therapeutic Agents IV: Small Molecule Inhibitors |
| Experimental and Molecular Therapeutics 40: Proteosome Inhibition and Histone Deacetylase Inhibitors |
| Integrated Session 9: Racial and Ethnic Minorities and the Medically Underserved: Multidisciplinary Research into Biology, Outcomes, and Disparities |
| Prevention Research 8: Mechanistic Pathways Modulated by Natural Products |
| Prevention Research 9: New Agents and Mechanisms in Chemoprevention of Prostate and Breast Cancer |
| Carcinogenesis 10: Signal Transduction and Gene Expression |
| Cellular, Molecular, and Tumor Biology 80: Angiogenesis Inhibitors III |
| Cellular, Molecular, and Tumor Biology 81: Apoptosis-inducing Agents |
| Cellular, Molecular, and Tumor Biology 82: Cell and Tissue Radiation Biology |
| Cellular, Molecular, and Tumor Biology 83: DNA Methylation and Chromatin |
| Cellular, Molecular, and Tumor Biology 84: DNA Methylation: New Genes |
| Cellular, Molecular, and Tumor Biology 85: Functional Analyses of Nuclear Oncogenes and Tumor Suppressors |
| Cellular, Molecular, and Tumor Biology 86: Gene Expression |
| Cellular, Molecular, and Tumor Biology 87: Genetic and Epigenetic Changes in Cancer |
| Cellular, Molecular, and Tumor Biology 88: Molecular Markers II |
| Cellular, Molecular, and Tumor Biology 89: Mouse Models of Prostate and Gastrointestinal Cancers |
| Cellular, Molecular, and Tumor Biology 90: Non-ionizing Radiation |
| Cellular, Molecular, and Tumor Biology 91: Receptor Tyrosine Kinase Signaling |
| Cellular, Molecular, and Tumor Biology 92: Regulation of Apoptosis I |
| Cellular, Molecular, and Tumor Biology 93: Signaling and Therapeutics II |
| Clinical Research 11: Clinical Investigations II: Gastrointestinal Cancers/Head and Neck Cancers/Hormone-related Cancers/ Leukemia and Lymphoma |
| Clinical Research 12: Clinical Investigations III: Lung Cancer/Ovarian and Other Gynecologic Cancers |
| Clinical Research 13: Clinical Investigations IV: Prostate and Other Genitourinary Cancers |
| Epidemiology 11: Genetic Epidemiology of Breast, Prostate, and Gynecologic Cancers: Hormone and Carcinogen Metabolism |
| Epidemiology 12: Polymorphisms in Diverse Genes Associated with Gastrointestinal Lesions |
| Experimental and Molecular Therapeutics 41: Antiangiogenesis |
| Experimental and Molecular Therapeutics 42: Cell and Stroma-directed New Agents |
| Experimental and Molecular Therapeutics 43: Gene Therapy III |
| Experimental and Molecular Therapeutics 44: Platinum Compounds/Antimetabolites/Taxanes |
| Experimental and Molecular Therapeutics 45: Small Molecules: Signaling and Apoptosis Targets |
| Immunology/Tumor Immunobiology 8: Lymphokines, Cytokines, and Growth Factors in Tumor Immunity II |
| Immunology/Tumor Immunobiology 9: Specific Immunomechanisms and Cancer Vaccines: Basic Studies III |
| Integrated Session 10: Human Prevention/Screening Studies |
| Clinical Research 14: Clinical Pharmacology/Pharmacogenomics |
| Carcinogenesis 11: Viral Carcinogenesis |
| Cellular, Molecular, and Tumor Biology 94: Advances in Proteomics Applied to Cancer Detection and Treatment |
| Cellular, Molecular, and Tumor Biology 95: Angiogenesis Mechanisms and Microenvironment |
| Cellular, Molecular, and Tumor Biology 96:: Bioinformatics and Cancer: Tools, Resources, and Biology |
| Cellular, Molecular, and Tumor Biology 97: Cell Surface Receptor Signaling |
| Cellular, Molecular, and Tumor Biology 98: Mechanisms of Apoptosis |
| Experimental and Molecular Therapeutics 46: Cell Signaling Inhibitors |
| Immunology/Tumor Immunobiology 10: Cancer Vaccines: Preclinical Studies |
| Carcinogenesis 12: Mutagenesis |
| Cellular, Molecular, and Tumor Biology 100: Activation of Apoptosis by Novel Therapeutic Agents |
| Cellular, Molecular, and Tumor Biology 101: Adhesion and Signaling in Cancer Progression |
| Cellular, Molecular, and Tumor Biology 102: Angiogenesis III |
| Cellular, Molecular, and Tumor Biology 103: Apoptosis Detection and Regulation |
| Cellular, Molecular, and Tumor Biology 99: DNA Methylation Profiles |
| Cellular, Molecular, and Tumor Biology 104: Kinase-mediated Cell Survival and Apoptosis |
| Cellular, Molecular, and Tumor Biology 105: Matrix and Adhesion in Cancer Metastasis I |
| Cellular, Molecular, and Tumor Biology 106: Matrix and Adhesion in Cancer Metastasis II |
| Cellular, Molecular, and Tumor Biology 107: Molecular Alterations in Gastrointestinal Tumor Formation |
| Cellular, Molecular, and Tumor Biology 108: Mouse Models of Human Cancer |
| Cellular, Molecular, and Tumor Biology 109: Preclinical Science and Imaging in Cancer Models |
| Cellular, Molecular, and Tumor Biology 110: Protein Kinase C Signaling |
| Cellular, Molecular, and Tumor Biology 111: Regulation of Apoptosis II |
| Cellular, Molecular, and Tumor Biology 112: Signaling and Therapeutics III |
| Chemistry 5: Proteomics and Chemistry |
| Clinical Research 15: Clinical Investigations V: Brain and Other CNS Tumors/Breast Cancer/Melanoma |
| Clinical Research 16: Molecular and Morphologic Tumor Staging/Imaging |
| Epidemiology 13: Genetic Susceptibility to Squamous and Transitional Cell Cancers |
| Experimental and Molecular Therapeutics 47: Cellular Responses to Anticancer Drugs |
| Experimental and Molecular Therapeutics 48: Growth Factor Receptors as Therapeutic Targets |
| Experimental and Molecular Therapeutics 49: Molecular Targeted Agents |
| Experimental and Molecular Therapeutics 50: New Approaches to Classic Targets |
| Experimental and Molecular Therapeutics 51: Pharmacokinetics and Pharmacodynamics |
| Experimental and Molecular Therapeutics 52: Tubulin-targeted Agents |
| Immunology/Tumor Immunobiology 11: Tumor Antigens and Animal Models for Immunotherapy I |
| Immunology/Tumor Immunobiology 12: Tumor Antigens and Animal Models for Immunotherapy II |
| Prevention Research 10: Biomarkers and Intervention Studies |
| Carcinogenesis 13: Animal and In Vitro Models of Carcinogenesis II |
| Cellular, Molecular, and Tumor Biology 113: Cytoplasmic Signaling by Oncogenes and Tumor Suppressors |
| Cellular, Molecular, and Tumor Biology 114: Molecular and Cellular Determinants of Radiation Response |
| Cellular, Molecular, and Tumor Biology 115: Nuclear Oncogenes and Tumor Suppressors |
| Cellular, Molecular, and Tumor Biology 116: Single and Multiple Gene Alterations in Murine Cancer Models |
| Cellular, Molecular, and Tumor Biology 117: Therapeutic Applications Based on Apoptotic Pathways |
| Clinical Research 17: Global Molecular Classification and Diagnosis |
| Endocrinology 5: Endocrinology V |
| Experimental and Molecular Therapeutics 53: Microtubule Inhibitors |
| Experimental and Molecular Therapeutics 54: Small Molecules: Cell Cycle and Signaling Inhibitors |
| Integrated Session 11: Proteomics |
| Best Abstracts Plenary Session |
| Educational Session: Chromatin Structure and Function in Cancer |
| Educational Session: RNA Interference: A Tool for Gene Silencing |
| Educational Session: Studying Genetic Modifiers in Experimental and Human Cancer |
| Educational Session: Targeting Signal Transduction Pathways |
| Educational Session: Zebrafish as an Animal Model in Cancer Research |
| Educational Session: Chemical Biology in Anticancer Drug Discovery |
| Educational Session: Research Paradigms in Anticancer Drug Discovery and Development |
| Educational Session: Stem Cells and Cancer |
| Educational Session: Molecular Imaging Strategies |
| Educational Session: Structural Biology and Its Practical Aspects in Drug Discovery |
| Educational Session: Advances in High-Throughput Genotyping |
| Educational Session: Biologic Agents as Radiation Response Modifiers |
| Educational Session: Hypoxia: Impact on Cancer Biology |
| Educational Session: Registration Strategies in Cancer Drug Development: Opportunities and Challenges |
| Symposium: Outside-In Signaling in Cancer |
| Symposium: Systems Biology of Cancer: The Tumor as an Organ |
| Opening Plenary Session: Targeting the Conquest of Cancer through Conceptual Integration and Innovation |
| Symposium: Pharmacogenomics and Response Prediction |
| Symposium: The Ubiquitin-Proteasome System and Cancer |
| Symposium: Genetic Model Systems to Dissect Cancer |
| Symposium: Genetic Modifiers of Cancer Risk |
| Symposium: Nuclear Receptors and Cancer Prevention |
| Symposium: DNA Damage Signaling |
| Symposium: Cellular and Molecular Determinants of Metastasis |
| Symposium: Genomic and Chromosomal Instability |
| Symposium: Obesity, Metabolism and Cancer |
| Symposium: Challenges for Integrating Targeted Therapies |
| Symposium: Role of DNA Repair Genotype and Phenotype in Cancer Susceptibility |
